SIPMeL

Login

067 - Therapeutic monitoring in liver transplant patients

Autor(s): M. Regazzi, M. Molinaro

Issue: RIMeL - IJLaM, Vol. 6, N. 3-S1, 2010 (MAF Servizi srl ed.)

Page(s): 67-69

Today immunosuppression therapies are frequently directed towards an individualized regimen, based on immunological risk. Immune suppressing regimens are not without risk and the subject in treatment must be carefully monitored. Therapeutic Drug Monitoring (TDM) represents an integral part of the immunosuppression regimen in solid organ transplantation, including liver transplantation. It should be emphasized that the drug concentration within the therapeutic range does not guarantee prevention of rejection nor does it circumvent toxicity in every patient, in every setting. The objective of TDM goes beyond the simple determination of drug quantification in the systemic circulation of the patient, but requires the interpretation of results in conjunction with clinical and biochemical parameters. More generally speaking, TDM of immunosuppressing drugs is evolving towards a more complex set of integrated decisions (pharmacokinetics, pharmacogenetics, pharmacodynamics), which must encompass the diverse co-variables that determine the individual pharmacological response, without neglecting to take into consideration the sensitivity and specificity of the analytical method utilized.

Article in PDF format

Back to current issue